Tags

Type your tag names separated by a space and hit enter

[Chronic kidney disease and statins].
Lijec Vjesn. 2006 Nov-Dec; 128(11-12):345-50.LV

Abstract

Dyslipidemia is a risk factor for de novo occurrence of renal disease in apparently healthy population, and diabetes, and contributes to progressive decline of renal function in diabetic and nondiabetic kidney disease. Chronic kidney disease and dyslipidemia, frequently occurring together, are independent cardiovascular risk factors. There is a strong association between the level of renal insufficiency and cardiovascular disease. According to available evidence, statin therapy may reduce cardiovascular risk in chronic kidney disease as well as modify its course, especially in patients with moderate impairment of renal function. However, all these findings must be examined in large-scale trials in patients with chronic renal disease and different stages of renal insufficiency. There are several on-going trials aimed at determing the role of statin therapy in this specific population, and confirming its efficacy in reducing cardiovascular risk and halting the progression of chronic kidney disease.

Authors+Show Affiliations

Matovinović MS
Klinika za unutarnje bolesti, Klinicka bolnica "Merkur", Zagreb. mirjana.sabljar-matovinovic@zg.htnet.hr

MeSH

Cardiovascular DiseasesChronic DiseaseDisease ProgressionDyslipidemiasHumansHydroxymethylglutaryl-CoA Reductase InhibitorsKidney Diseases

Pub Type(s)

English Abstract
Journal Article

Language

hrv

PubMed ID

17212196

Citation

Matovinović, Mirjana Sabljar. "[Chronic Kidney Disease and Statins]." Lijecnicki Vjesnik, vol. 128, no. 11-12, 2006, pp. 345-50.
Matovinović MS. [Chronic kidney disease and statins]. Lijec Vjesn. 2006;128(11-12):345-50.
Matovinović, M. S. (2006). [Chronic kidney disease and statins]. Lijecnicki Vjesnik, 128(11-12), 345-50.
Matovinović MS. [Chronic Kidney Disease and Statins]. Lijec Vjesn. 2006 Nov-Dec;128(11-12):345-50. PubMed PMID: 17212196.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Chronic kidney disease and statins]. A1 - Matovinović,Mirjana Sabljar, PY - 2007/1/11/pubmed PY - 2007/2/16/medline PY - 2007/1/11/entrez SP - 345 EP - 50 JF - Lijecnicki vjesnik JO - Lijec Vjesn VL - 128 IS - 11-12 N2 - Dyslipidemia is a risk factor for de novo occurrence of renal disease in apparently healthy population, and diabetes, and contributes to progressive decline of renal function in diabetic and nondiabetic kidney disease. Chronic kidney disease and dyslipidemia, frequently occurring together, are independent cardiovascular risk factors. There is a strong association between the level of renal insufficiency and cardiovascular disease. According to available evidence, statin therapy may reduce cardiovascular risk in chronic kidney disease as well as modify its course, especially in patients with moderate impairment of renal function. However, all these findings must be examined in large-scale trials in patients with chronic renal disease and different stages of renal insufficiency. There are several on-going trials aimed at determing the role of statin therapy in this specific population, and confirming its efficacy in reducing cardiovascular risk and halting the progression of chronic kidney disease. SN - 0024-3477 UR - https://www.unboundmedicine.com/medline/citation/17212196/[Chronic_kidney_disease_and_statins]_ L2 - http://www.diseaseinfosearch.org/result/3996 DB - PRIME DP - Unbound Medicine ER -